TY - JOUR A2 - Karakousis, Constantine P. AU - Lorusso, D. AU - Mancini, M. AU - Di Rocco, R. AU - Fontanelli, R. AU - Raspagliesi, F. PY - 2012 DA - 2012/08/05 TI - The Role of Secondary Surgery in Recurrent Ovarian Cancer SP - 613980 VL - 2012 AB - Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described. SN - 2090-1402 UR - https://doi.org/10.1155/2012/613980 DO - 10.1155/2012/613980 JF - International Journal of Surgical Oncology PB - Hindawi Publishing Corporation KW - ER -